Inhibitory effect of granulocyte-macrophage colony-stimulating factor therapy on the generation of natural killer cells.
We investigated the effects of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and recombinant human granulocyte colony-stimulating factor (rhG-CSF) therapy on the natural killer (NK) cell lineage in patients with aplastic anemia and myelodysplastic syndrome. Selected bone marrow (BM) cells were prepared by the elimination of nylon wool-adherent cells and mature T and NK cells from BM cells. The frequency of BM NK progenitors relative to BM cells selected was significantly decreased 4 weeks after the start of rhGM-CSF therapy (P less than .01), while the peripheral blood NK cell count and NK activity were also significantly decreased (P less than .05). A return to the pretreatment levels was seen 4 weeks after the cessation of treatment in all cases. No suppressive effect was noted in the patients who received rhG-CSF therapy. These results suggest that rhGM-CSF therapy suppresses the generation of NK cells from human BM NK progenitors.
Shibuya
A
A
Division of Hematology, University of Tsukuba, Ibaraki, Japan.
Taguchi
K
K
Kojima
H
H
Abe
T
T
D000741:Anemia, Aplastic / Q000188:drug therapy / Q000473:pathology*; D001853:Bone Marrow / Q000473:pathology; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects* / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000009:adverse effects* / Q000627:therapeutic use; D006412:Hematopoietic Stem Cells / Q000473:pathology; D006801:Humans; D007694:Killer Cells, Natural / Q000473:pathology*; D007958:Leukocyte Count; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000473:pathology*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor